Ocular Therapeutix Inc (NASDAQ: OCUL) is 102.69% higher on its value in year-to-date trading and has touched a low of $2.00 and a high of $11.31 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The OCUL stock was last observed hovering at around $9.05 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $9.04, the stock is 3.36% and 8.23% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.3 million and changing -0.11% at the moment leaves the stock 33.31% off its SMA200. OCUL registered 165.88% gain for a year compared to 6-month loss of -8.69%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 2.26% gain in the last 1 month and extending the period to 3 months gives it a 48.68%, and is 3.79% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.64% over the week and 4.72% over the month.
Ocular Therapeutix Inc (OCUL) has around 267 employees, a market worth around $1.41B and $61.10M in sales. Profit margin for the company is -226.46%. Distance from 52-week low is 353.13% and -20.07% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.68%).
Ocular Therapeutix Inc quarterly earnings per share for the current quarter are estimated at -0.24 with sales reaching $17.13M over the same period.The EPS is expected to shrink by -16.21% this year, but quarterly earnings will post 13.20% year-over-year.
203.0 institutions hold shares in Ocular Therapeutix Inc (OCUL), with institutional investors hold 89.96% of the company’s shares. The shares outstanding are 155.92M, and float is at 135.52M with Short Float at 13.54%. Institutions hold 89.13% of the Float.
The top institutional shareholder in the company is SUMMER ROAD LLC with over 14.89 million shares valued at $101.82 million. The investor’s holdings represent 11.2751 of the OCUL Shares outstanding. As of 2024-06-30, the second largest holder is VR ADVISER, LLC with 12.76 million shares valued at $87.3 million to account for 9.6669 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 12.72 million shares representing 9.6359 and valued at over $87.01 million, while BLACKROCK INC. holds 8.7261 of the shares totaling 11.52 million with a market value of $78.8 million.
Ocular Therapeutix Inc (OCUL) Insider Activity
The most recent transaction is an insider sale by Nayak Sanjay, the company’s Chief Strategy Officer. SEC filings show that Nayak Sanjay sold 1,832 shares of the company’s common stock on Aug 23 ’24 at a price of $9.02 per share for a total of $16525.0. Following the sale, the insider now owns 0.18 million shares.
Ocular Therapeutix Inc disclosed in a document filed with the SEC on Aug 23 ’24 that Dugel Pravin sold a total of 20,880 shares of the company’s common stock. The trade occurred on Aug 23 ’24 and was made at $9.02 per share for $0.19 million. Following the transaction, the insider now directly holds 0.81 million shares of the OCUL stock.
Still, SEC filings show that on Aug 27 ’24, RABIA OZDEN (Officer) Proposed Sale 18,333 shares at an average price of $9.00 for $0.16 million. The insider now directly holds shares of Ocular Therapeutix Inc (OCUL).
